

Evonik at HPCI Congress Middle East & Eurasia

June 01, 2010

New Inspiring Active Ingredients for Cosmetics

In cooperation with ELKASAN Kimyevi Maddeler Pazarlama A.S., the Personal Care product line of Evonik showcases a unique and comprehensive portfolio of personal care products and technologies to the Middle East and Eurasian Markets at the 2010 HPCI Congress in Istanbul, June 9–10 (Booth No. 480).

Dr. Hans-Georg Kreul
Consumer Specialties
Public Relations
Phone +49 201 173-2415
Fax +49 201 173-1838
hans.kreul@evonik.com

Exciting concepts and new product innovation designed to help formulators perfecting the performance and efficiency of their cosmetic formulations will be present at the congress. Bioengineer Jennifer Lange will give a lecture on “Anti-aging: a multifunctional concept based on Hyaluronic Acid and Peptides”. (June 9th, 15:15–15:30).

Cross-linked Hyaluronic Acid is well known for its use as dermal filler. Dermatologists inject it directly into the skin to physically fill up wrinkles from the inside. But many consumers do not like such an invasive and expensive approach. Therefore, they are looking for cosmetics alternatives based on formulations which mimic the immediate wrinkle reducing properties of dermal fillers. To fulfil this need, HyaCare® Filler CL, the topical wrinkle smoother, will be launched for the instant reduction of facial fine lines and wrinkles. Because of its high water-binding and strong short-term moisturization properties, HyaCare® Filler CL effectively supports the hydration of the skin. In addition, it retains its positive effects of improved skin elasticity.

Evonik Goldschmidt GmbH
Goldschmidtstrasse 100
45127 Essen/Germany
Phone +49 201 173 01
Fax +49 201 173 3000
www.evonik.com

Supervisory Board
Patrik Wohlhauser, Chairman
Board of Management
Dr. Claus Rettig Chairman
Willibrord Lampen

June 01, 2010

TEGO® Pep 4-17 is a skin identical, pure and bioactive tetrapeptide with excellent ECM boosting activity (collagen, hyaluronic acid and fibronectin). It is ideal for anti-wrinkle preparations because it minimizes the appearance of all kinds of wrinkles and reduces skin roughness. Tetrapeptide-21 is identified by an *in silico* approach and patent protected by Evonik. The activity of TEGO® Pep 4-17 is supported by strong *in vivo* data, including a facial anti-wrinkle study.

Dr. Hans-Georg Kreul
Public Relations Consumer Specialties
Phone +49 201 173-2415
Fax +49 201 173-1838
hans.kreul@evonik.com

About Evonik

Evonik Industries is the creative industrial group from Germany. In our core business of specialty chemicals, we are a global leader. In addition, Evonik is an expert in power generation from hard coal and renewable energies, and one of the largest private residential real estate companies in Germany. Our company's performance is shaped by creativity, specialization, continuous self-renewal, and reliability.

Evonik is active in over 100 countries around the world. In its fiscal year 2009 about 39,000 employees generated sales of about €13.1 billion and an operating profit (EBITDA) of about €2.0 billion.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.

Evonik Goldschmidt GmbH
Goldschmidtstrasse 100
45127 Essen/Germany
Phone +49 201 173 01
Fax +49 201 173 3000
www.evonik.com

Supervisory Board
Patrik Wohlhauser
Board of Management
Dr. Claus Rettig Chairman
Willibrord Lampen